|
| 37269078 | Perspectives of adolescents with neurofibromatosis 1 and cutaneous neurofibromas: Implications for clinical trials. | Clin Trials | 2024 |
| 36980006 | The Perceived Influence of Neurofibromatosis Type 1(NF1) on the Parents' Relationship. | | 2023 |
| 36302175 | A Phase II Trial of Guadecitabine in Children and Adults with SDH-Deficient GIST, Pheochromocytoma, Paraganglioma, and HLRCC-Associated Renal Cell Carcinoma. | Clin Cancer Res | 2023 |
| 35882475 | Doxorubicin pharmacokinetics and toxicity in patients with aggressive lymphoma and hepatic impairment. | Blood Adv | 2023 |
| 37585199 | Estimated Prevalence, Tumor Spectrum, and Neurofibromatosis Type 1-Like Phenotype of CDKN2A-Related Melanoma-Astrocytoma Syndrome. | JAMA Dermatol | 2023 |
| 37877369 | Development and pilot validation of a novel disfigurement severity scale for plexiform neurofibromas in children with neurofibromatosis type 1. | | 2023 |
| 37776044 | Advancing neurofibromatosis and schwannomatosis clinical trial design: Consensus recommendations from the Response Evaluation in Neurofibromatosis and Schwannomatosis (REiNS) International Collaboration. | | 2023 |
| 37347686 | The NIH pediatric/young adult chordoma clinic and natural history study: Making advances in a very rare tumor. | Pediatr Blood Cancer | 2023 |
| 37345354 | NCI intramural program approach to rare tumors: Natural history study of rare solid tumors in children and adults: A longitudinal, comprehensive data and biospecimen collection protocol. | Pediatr Blood Cancer | 2023 |
| 36592025 | Advances, challenges and progress in pediatric hematology and oncology. | | 2023 |
| 37029730 | Surgery and proton radiation therapy for pediatric base of skull chordomas: Long-term clinical outcomes for 204 patients. | Neuro Oncol | 2023 |
| 36583617 | Audiometric and Otologic Findings in Children and Young Adults with Neurofibromatosis Type 1 and Plexiform Neurofibromas. | | 2023 |
| 37398992 | Phase I trial of Ganitumab plus Dasatinib to Cotarget the Insulin-Like Growth Factor 1 Receptor and Src Family Kinase YES in Rhabdomyosarcoma. | Clin Cancer Res | 2023 |
| 37267580 | The Childhood Cancer Data Initiative: Using the Power of Data to Learn From and Improve Outcomes for Every Child and Young Adult With Pediatric Cancer. | J Clin Oncol | 2023 |
| 36750981 | Longitudinal association between executive function and academic achievement in children with neurofibromatosis type 1 and plexiform neurofibromas. | | 2023 |
| 36799629 | MEK Inhibition Synergizes with TYK2 Inhibitors in NF1-Associated Malignant Peripheral Nerve Sheath Tumors. | Clin Cancer Res | 2023 |
| 37244583 | Retrospective Cohort Analysis of the Impact of Puberty on Plexiform Neurofibroma Growth in Patients with Neurofibromatosis Type 1. | | 2023 |
| 37115514 | Long-term safety and efficacy of selumetinib in children with neurofibromatosis type 1 on a phase 1/2 trial for inoperable plexiform neurofibromas. | Neuro Oncol | 2023 |
| 36724001 | Outcome of Patients With Malignant Peripheral Nerve Sheath Tumors Enrolled on Sarcoma Alliance for Research Through Collaboration (SARC) Phase II Trials. | | 2023 |
| 35007270 | Robotic Nerve Sheath Tumor Resection With Intraoperative Neuromonitoring: Case Series and Systematic Review. | Operative Neurosurgery | 2022 |
| 35657359 | Management of neurofibromatosis type 1-associated plexiform neurofibromas. | Neuro Oncol | 2022 |
| 35740711 | Psychosocial Characteristics and Experiences in Patients with Multiple Endocrine Neoplasia Type 2 (MEN2) and Medullary Thyroid Carcinoma (MTC). | Children | 2022 |
| 36130486 | Single-cell sequencing reveals activation of core transcription factors in PRC2-deficient malignant peripheral nerve sheath tumor. | Cell Reports | 2022 |
| 35791896 | Reporting of Racial and Ethnic Minority Representation in Early Phase Pediatric Oncology Clinical Trials. | Oncologist | 2022 |
| 35788692 | MEK inhibitors for neurofibromatosis type 1 manifestations: Clinical evidence and consensus. | Neuro Oncol | 2022 |
| 36387865 | Pediatric adrenocortical carcinoma. | Front Endocrinol (Lausanne) | 2022 |
| 35467749 | Selumetinib in children with neurofibromatosis type 1 and asymptomatic inoperable plexiform neurofibroma at risk for developing tumor-related morbidity. | Neuro Oncol | 2022 |
| 36497438 | Demographic and Disease-Related Predictors of Socioemotional Development in Children with Neurofibromatosis Type 1 and Plexiform Neurofibromas: An Exploratory Study. | | 2022 |
| 35334353 | Verbal learning and memory in youth with neurofibromatosis type 1 and plexiform neurofibromas: Relationships with disease severity. | European Journal of Paediatric Neurology | 2022 |
| 34731530 | Adolescents and young adults with neurofibromatosis type 1: A descriptive study of adaptive functioning. | American Journal of Medical Genetics, Part A | 2022 |
| 34479925 | Phase 1 open-label trial of intravenous administration of MVA-BN-brachyury-TRICOM vaccine in patients with advanced cancer. | Journal for ImmunoTherapy of Cancer | 2021 |
| 34230202 | Perspective of Adults With Neurofibromatosis 1 and Cutaneous Neurofibromas: Implications for Clinical Trials. | Neurology | 2021 |
| 34230201 | [REiNS] NF Clinical Trials - REiNS Collaboration 2020 Recommendations: Looking Back and Moving Ahead. | Neurology | 2021 |
| 34230196 | Reliability of Handheld Dynamometry to Measure Focal Muscle Weakness in Neurofibromatosis Types 1 and 2. | Neurology | 2021 |
| 33536190 | Isoform- and Phosphorylation-specific Multiplexed Quantitative Pharmacodynamics of Drugs Targeting PI3K and MAPK Signaling in Xenograft Models and Clinical Biopsies. | Mol Cancer Ther | 2021 |
| 34266694 | Chordoma: Current status, problems, and future directions. | Current Problems in Cancer | 2021 |
| 33836455 | Ataxia telangiectasia mutated germline pathogenic variant in adrenocortical carcinoma. | Cancer Genet | 2021 |
| 33615670 | Case report of adrenocortical carcinoma associated with double germline mutations in MSH2 and RET. | Am J Med Genet A | 2021 |
| 33507822 | NF106: A Neurofibromatosis Clinical Trials Consortium Phase II Trial of the MEK Inhibitor Mirdametinib (PD-0325901) in Adolescents and Adults With NF1-Related Plexiform Neurofibromas. | J Clin Oncol | 2021 |
| 33978635 | Selumetinib normalizes Ras/MAPK signaling in clinically relevant neurofibromatosis type 1 minipig tissues in vivo. | Neurooncol Adv | 2021 |
| 34304884 | Editorial: Special issue on rare cancers. | Curr Probl Cancer | 2021 |
| 33289920 | SARC025 arms 1 and 2: A phase 1 study of the poly(ADP-ribose) polymerase inhibitor niraparib with temozolomide or irinotecan in patients with advanced Ewing sarcoma. | Cancer | 2021 |
| 32852366 | Are Some Randomized Clinical Trials Impossible? | Journal of Pediatric Orthopaedics | 2021 |
| 34464388 | Cell-free DNA ultra-low-pass whole genome sequencing to distinguish malignant peripheral nerve sheath tumor (MPNST) from its benign precursor lesion: A cross-sectional study. | PLoS Med | 2021 |
| 34898541 | Tumor Doubling Time Using CT Volumetric Segmentation in Metastatic Adrenocortical Carcinoma. | Curr Oncol | 2021 |
| 34383370 | Phase 1 study of sorafenib and irinotecan in pediatric patients with relapsed or refractory solid tumors. | Pediatric Blood and Cancer | 2021 |
| 34377779 | Impact of MEK Inhibitor Therapy on Neurocognitive Functioning in NF1. | Neurol Genet | 2021 |
| 32939452 | The MEK inhibitor selumetinib reduces spinal neurofibroma burden in patients with NF1 and plexiform neurofibromas. | Neuro-Oncology Advances | 2020 |
| 31913576 | Advancing RAS/RASopathy therapies: An NCI-sponsored intramural and extramural collaboration for the study of RASopathies. | Am J Med Genet A | 2020 |
| 32187457 | Selumetinib in Children with Inoperable Plexiform Neurofibromas. | N Engl J Med | 2020 |